Bibliography

Bibliography

Healthcare professionals may request a full copy of the cited clinical trial report from Vifor Pharma Switzerland.

• Al Hussain T, et al. Pathophysiology of ANCA-associated Vasculitis. Adv Anat Pathol 2017;24(4):226–34.
• Basu N, et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis 2014;73(1):207–11.
• Bekker P, et al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One 2016;11(10):e0164646.
• Charles P, et al. Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis. Ann Intern Med 2020;173(3):179–87.
• Cortazar F, et al. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. Kidney Int Rep 2023;8(4):860–70.
• EMA. First-in-class medicine recommended for treatment of rare blood vessel inflammation. Nov. 2021. https://www.ema.europa.eu/en/news/first-class-medicine-recommended-treatment-rare-blood-vessel-inflammation. Last access: October 2023.
• Hellmich B, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 2023;0:1–18.
• Hunter RW, et al. ANCA-associated vasculitis. BMJ 2020;369:m1070.
• Hutton HL, et al. ANCA-associated vasculitis: pathogenesis, models, and preclinical testing. Semin Nephrol 2017;37(5):418–35.
• Jayne D, Bekker. Integrated Safety of Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol 2022;33:794–5 (Abstract SA-PO696).
• Jayne D, et al. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med2021;384(7):599–609.
• Jayne D, et al. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med2021;384(7):599–609. [Supp Appendix].
• Jennette JC, Nachman PH. ANCA Glomerulonephritis and Vasculitis. Clin J Am Soc Nephrol 2017;12(10):1680–91.
• Kitching AR, et al. ANCA-associated vasculitis. Nat Rev Dis Primers 2020;6(1):71.
• Lamprecht P, et al. Mind the Gap: Balancing Remission and Risk of Relapse in ANCA-Associated Vasculitis. EMJ Rheumatol 2021;8(1):36–42.
• Liberman AC, et al. Regulatory and Mechanistic Actions of Glucocorticoids on T and Inflammatory Cells. Front Endocrinol (Lausanne) 2018;9:235.
• Little MA, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010;69(6):1036–43.
• McDowell P, et al. Quantification of Glucocorticoid-associated morbidity in Severe Asthma using the Glucocorticoid Toxicity Index. J Allergy Clin Immunol Pract 2021;9(1):365–72.
• McGregor JG, et al. Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease. Clin J Am Soc Nephrol 2012;7(2):240–7.
• Nozaki Y. New insights into novel therapeutic targets in ANCA-associated vasculitis. Front Immunol 2021;12:631055.
• Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol 2016;3(3):122–33.
• Quartuccio L, et al. Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors. J Autoimmun 2020;108:102397.
• Robson J, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford) 2015;54(3):471–81.
• Specks U, et al. Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. N Engl J Med 2013;369(5):417–27.
• Stone J, et al. The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time. Semin Arthritis Rheum 2022;55:152010.
• Stone JH, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. N Engl J Med 2010;363(3):221–32.
• Strand V, et al. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol 2023;5:e451–60.
• TAVNEOS® Fachinformation, www.swissmedicinfo.ch.
• Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006;176(3):1305–10.
• Turnbull J, Harper L. Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol 2009;23(3):391–401.
• Wallace ZS, Miloslavsky EM. Management of ANCA associated vasculitis. BMJ 2020;368:m421.
• Walsh M, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med 2020;382(7):622–31.
• Yates M, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75(9):1583–94.